IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones .
15 mayo 2008
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer .
Verified by National Cancer Institute (NCI), May 2008
Entrada más reciente
Entrada antigua
Inicio